1 September 2024
Clinical trial update (ASX Announcement)
Melbourne, Australia; 27 June 2023: A voluntary partial clinical hold has been implemented on a trial in which Starpharma (ASX: SPL, OTCQX: SPHRY) technology is used: AZD0466 Monotherapy or in Combination in Patients with Advanced Haematological Malignancies (NCT04865419). This Phase 1/2 study is in the dose escalation phase.
The asymptomatic reported events leading to the voluntary partial hold were assessed as not related to Starpharma’s DEP® dendrimer. The voluntary partial clinical hold does not impact
Starpharma’s platform technology, or other clinical DEP® programs or partnerships.
The other clinical study of AZD0466 in patients with non-Hodgkin’s lymphoma (NCT05205161) is not impacted and continues to enroll patients.
Starpharma will provide further details to the market when additional relevant information becomes available. AstraZeneca (LSE/STO/Nasdaq: AZN) is the study sponsor.
View or download the ASX Announcement here.